Searchable abstracts of presentations at key conferences in endocrinology

ea0060nets2 | Diagnostic and Management Challenges in NETs | UKINETS2018

Chemotherapy: “is this the end of an old friend”

Valle Juan W

Chemotherapy has historically been the ‘work horse’ of medical oncology. An improved understanding of the biological behavious of neuroendocrine neoplasms has led to decision-making based on pathological characterisation of neuroendocrine neoplasms in to well-differentiated neuroendocrine tumours (NETs) vs poorly-differentiated neuroendocrine carcinomas (NECs). Platinum/etoposide has an established role in high-grade NECs with high responses, although these are often...

ea0025s2.3 | Novel pathways and treatments in neuroendocrine tumours | SFEBES2011

Tyrosine kinase inhibitors for neuroendocrine tumours

Valle Juan W

Neuroendocrine tumours (NETs) are a heterogeneous, uncommon tumours for whom there have been few practice-changing clinical studies. Sub-groups of patients may be defined by site of origin, histological sub-type, mitotic activity and evidence of disease progression.Chemotherapy is active in patients with advanced pancreatic NETs; however, benefits are modest and associated with significant (albeit manageable) toxicity. Additional treatment options are sp...

ea0052p15 | (1) | UKINETS2017

Platinum-etoposide chemotherapy for extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC): A survey of clinical practice

Lamarca Angela , Frizziero Melissa , Barriuso Jorge , McNamara Mairead G , Hubner Richard A , Valle Juan W

Introduction: Platinum-etoposide chemotherapy is a globally established chemotherapy combination for EP-G3-NEC. However, there are many different schedules for such chemotherapy, and the preferred one for EP-G3-NEC has not been established.Methods: An international survey was created, and completed by colleagues with an expertise in the field of neuroendocrine neoplasms. The aim was to explore which schedules of platinum-etoposide chemotherapy are used a...

ea0068p14 | Abstracts | UKINETS2019

Liver embolisation for patients diagnosed with neuroendocrine neoplasms: systematic review and meta-analysis of the literature

Kanabar Rahul , Barriuso Jorge , McNamara Mairead , Mansoor Was , Hubner Richard , Valle Juan , Lamarca Angela

Background: Liver embolisation is one of the treatment options available for patients diagnosed with neuro-endocrine neoplasms (NEN), especially in the presence of carcinoid syndrome. It is still uncertain whether the benefits of the various types of embolisation treatments truly outweigh the complications in NENs. This systematic review assesses the available data relating to liver embolisation in patients with NENs.Methods: Eligible studies (identified...

ea0034p45 | Clinical biochemistry | SFEBES2014

Serum 5HIAA: a better biomarker than urine for detecting and monitoring neuroendocrine tumours?

Adaway Joanne , Dobson Rebecca , Walsh Jennifer , Cuthbertson Daniel , Monaghan Philip , Valle Juan , Devlin Neil , Keevil Brian

Background: 5-hydroxyindole acetic acid (5-HIAA) (a metabolite of serotonin) is used as a marker for patients with serotonin-secreting neuroendocrine tumours. Currently, most laboratories measure 24 h 5-HIAA excretion in urine samples. Urine collections are cumbersome for the patient and impact on their daily activities; they are consequently often poorly performed, leading to over- or under-collection of urine and inaccurate 5-HIAA excretion results. Furthermore, large volume...

ea0031p48 | Clinical biochemistry | SFEBES2013

A comparison of serum chromogranin A measurement with 24 h urine and serum 5-hydroxyindole acetic acid measurement in patients with NETs

Monaghan Phillip , Adaway Joanne , Valle Juan , Hubner Richard , Trainer Peter , Darby Denise , Keevil Brian

Introduction: Chromogranin-A (CgA) is a 49 kDa protein of the granin/secretogranin family originating from dense-core secretory granules within cells of the diffuse endocrine system. CgA is currently the best available diagnostic biomarker for neuroendocrine tumours (NETs) with recent clinical guidelines advocating the measurement of CgA as part of the baseline biochemical profile in patients presenting with symptoms suspicious of a gastroenteropancreatic NET.<p class="abs...

ea0087oc3 | Oral Communications | UKINETS2022

Outcomes in patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumours receiving PRRT early versus later

Robinson Matthew D , Chander Amarjot , Westwood Tom , Manoharan Prakash , Mansoor Was , Lamarca Angela , A Hubner Richard , W Valle Juan , G McNamara Mairead

Background: Neuroendocrine tumours (NETs) are rare malignancies; over 60% of primary lesions arise in the gastrointestinal tract and pancreas. Despite several practice-changing clinical trials, uncertainty persists around the most efficacious treatment sequence in patients with advanced well-differentiated gastroenteropancreatic (GEP) NETs, particularly in relation to peptide receptor radionuclide therapy (PRRT). This study aimed to investigate the progression-free survival (P...

ea0068p6 | Abstracts | UKINETS2019

Hepatic arterial embolisation for patients diagnosed with neuroendocrine neoplasms: experience from a European Neuroendocrine Tumour Society centre of excellence

Nuttall Christina , Lamarca Angela , McNamara Mairead , Barriuso Jorge , Lawrance Jeremy , Mullan Damian , Mansoor Was , Valle Juan , Hubner Richard

Background: Hepatic arterial embolisation (HAE) is a recommended treatment option for patients with neuro-endocrine neoplasms (NENs) and liver metastasis. We aimed to describe outcomes after HAE for NENs at a single United Kingdom centre and investigate the influence of tumour characteristics.Methods: Retrospective analysis of sequential patients with NENs undergoing HAE at The Christie NHS Foundation Trust between 2004 and 2018. Primary end points were ...

ea0046p2 | (1) | UKINETS2016

68Gallium-DOTANOC (68Ga-DOTANOC) positron emission tomography (PET) imaging in Bronchial Carcinoids (BC): multicentre evaluation of its role in clinical practice

Lamarca Angela , Pritchard D. Mark , Westwood Thomas , Papaxoinis George , Vinjamuri Sobhan , Valle Juan W , Manoharan Prakash , Mansoor Wasat

Background: New nuclear medicine imaging techniques have improved diagnosis, staging and treatment planning for BC. 68Ga-DOTA PET is preferable to standard somatostatin receptor scintigraphy where available (ENETS guidelines); however, its role in the management of BC remains unclear.Methods: All consecutive patients diagnosed with BC from two ENETS Centres of Excellence were identified retrospectively; patients with high grade tumours or lack...

ea0046p3 | (1) | UKINETS2016

Health-related quality of life (HRQoL), anxiety, depression and impulsivity in patients with advanced Gastroenteropancreatic Neuroendocrine Tumours (GEPNETs)

Lewis Alexandra , Wang Xin , Magdalani Laurice , Bashir Colsom , Mansoor Wasat , Hubner Richard A , Valle Juan W , McNamara Mairead G

Background: In patients with advanced GEPNETs, psychological symptoms may result due to potential disturbances in biogenic amines, particularly serotonin. This study compared HRQoL, anxiety, depression, and impulsivity in patients with and without carcinoid syndrome (CS) and correlated with serum 5-HIAA.Methods: Consecutive patients with advanced GEPNETs (with liver metastases) receiving treatment, with and without CS completed (single time-point) HRQoL ...